TriSalus Life Sciences (TLSI) Net Income towards Common Stockholders (2021 - 2026)

TriSalus Life Sciences' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 113.88% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was -$58.5 million, a 92.95% decrease from a year earlier, with the FY2025 full-year figure at -$69.7 million, down 109.7% from the prior year.
• Net Income towards Common Stockholders improved to $1.5 million in Q1 2026 per TLSI's latest filing, from -$9.8 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $2.3 million in Q1 2022 and bottomed at -$41.3 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$9.2 million (2023), against an average of -$11.5 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 2419.36% in 2022; the steepest drop was 4565.49% in 2022.
• Year by year, Net Income towards Common Stockholders stood at -$25.4 million in 2022, then sank by 43.62% to -$36.4 million in 2023, then surged by 70.11% to -$10.9 million in 2024, then climbed by 10.45% to -$9.8 million in 2025, then soared by 115.78% to $1.5 million in 2026.
• Per Business Quant, the three latest TLSI Net Income towards Common Stockholders figures stand at $1.5 million (Q1 2026), -$9.8 million (Q4 2025), and -$41.3 million (Q3 2025).